Nonalcoholic Steatohepatitis Drugs Pipeline Market Prospects and Growth Assessment 2028

Nonalcoholic Steatohepatitis Drugs Pipeline Market Overview

Nonalcoholic Steatohepatitis Drugs Pipeline Analysis 2017

Non-alcoholic steatohepatitis (NASH) is a rare disease of liver characterized by buildup of fat in the liver. Prevalence of Nonalcoholic steatohepatitis is increasing parallel to prevalence of obesity across the globe. Non-alcoholic steatohepatitis is caused by insulin resistance and accumulation of toxic lipid metabolites of triglycerides. Several new drugs are being evaluated in clinical trials for the treatment of non-alcoholic steatohepatitis, however, there is no approved drugs available till now. Several molecules are about to complete phase 2 clinical trial and are entering in the most complex phase 3. According to Covance, Inc. survey NASH is the most common liver disease among obesity patients and affects over 60% of the obese population. Cirrhosis due to non-alcoholic steatohepatitis is the third most common cause of liver transplantation in the U.S. The global burden of NASH is increasing every year and there is an urgent need to develop effective treatment for non-alcoholic steatohepatitis. There is a rich pipeline of drugs being studied for non-alcoholic steatohepatitis treatment with huge range of products with different mechanism.

Non-alcoholic Steatohepatitis Drugs Pipeline: Drivers and Restraints

Growing pace of research activities and stimulation of funding are the factors supporting the growth of pipeline activities in non-alcoholic steatohepatitis treatment. More number of clinical candidates are advancing to late stages of development, which are expected to be launched in the global market within the course of next 8 years. For instance, currently there are four drugs being studied in phase 3 clinical trial, with wide range of mechanisms. Intercept Pharmaceuticals is evaluating its lead molecule- farnesoid X receptor acting agent in metacentric phase 3 trial. Genfit’s Elafibranor has reached phase 3, which is peroxisome proliferator-activated receptor alpha/delta agonist. Two more drugs in phase 3 trial include Tobira Therapeutics’ Cenicriviroc and Gilead’s selonsertib. Failure of these drugs in late stage would cause huge financial losses to the sponsors, which is the biggest risk factor for non-alcoholic steatohepatitis drugs pipeline.

Non-alcoholic Steatohepatitis Drugs Pipeline: Overview

There are range of pipeline drugs that target different pathways for synthesis of fatty acid and fibrosis and studies are being conducted to for application of these drugs in combination with existing drugs that are being used for treatment of obesity. There are more than 20 programs that are in phase 2b or phase 2a, which are evaluating candidates for non-alcoholic steatohepatitis treatment. Some of these candidates are performing exceptionally well in clinical trials. For instance, Gilead’s ACC inhibitor GS-0976 showed 43% decrease in hepatic steatosis and 9% reduction in liver stiffness in phase 2

Non-alcoholic Steatohepatitis Drugs Pipeline: Regional Overview

Geographically, the global non-alcoholic steatohepatitis drugs pipeline report is divided into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominates the global clinical trial activities in non-alcoholic steatohepatitis treatment with over 200 active clinical trials being carried out in the U.S. and Canada. Western Europe witnesses the second largest magnitude of clinical activities in non-alcoholic steatohepatitis treatment with over 120 active clinical trials. Japan shows low level of research activities in non-alcoholic steatohepatitis.

For more insights into the market, request a sample of this [email protected] https://www.futuremarketinsights.com/reports/sample/rep-gb-6719

Nonalcoholic Steatohepatitis Drugs: Key Players

Some of the key players having nonalcoholic steatohepatitis drugs in their pipeline include Tobira Therapeutics, Inc., Genfit SA, Intercept Pharmaceuticals Inc., Gilead Sciences, Inc., Bristol-Mayers Squibb and Comnay, Merck KGaA, NGM Biopharmaceuticals, Galectin Therapeutics Inc., Madaus Inc. etc. among others.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-6719

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: [email protected]
For Media Enquiries: [email protected]
Website: https://www.futuremarketinsights.com

Leave a Comment

%d bloggers like this: